Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care. Article uri icon

Overview

publication date

  • December 14, 2017

Research

keywords

  • Antineoplastic Agents
  • Glycine
  • Myelodysplastic Syndromes
  • Sulfones
  • Treatment Outcome

Identity

PubMed Central ID

  • PMC5802598

Scopus Document Identifier

  • 85038437972

Digital Object Identifier (DOI)

  • 10.1038/s41408-017-0018-7

PubMed ID

  • 29238044

Additional Document Info

volume

  • 7

issue

  • 12